NVCR NovoCure Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: NVCR

Price (delayed)

$57.17

Market cap

$6.03B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.88

Enterprise value

$6.5B

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating ...

Highlights
The equity has increased by 7% year-on-year
The net income has plunged by 59% YoY and by 13% from the previous quarter
NVCR's EPS has dropped by 57% year-on-year and by 14% since the previous quarter
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.novocure.com
Peers: MRVI MGTX NBIX

Key stats

What are the main financial stats of NVCR
Market
Shares outstanding
105.46M
Market cap
$6.03B
Enterprise value
$6.5B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
13.6
Price to sales (P/S)
11.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.08
Earnings
Revenue
$537.84M
EBIT
-$89.52M
EBITDA
-$78.9M
Free cash flow
$9.43M
Per share
EPS
-$0.88
Free cash flow per share
$0.09
Book value per share
$4.2
Revenue per share
$5.14
TBVPS
$11.39
Balance sheet
Total assets
$1.19B
Total liabilities
$750.48M
Debt
$584.27M
Equity
$441.17M
Working capital
$952.75M
Liquidity
Debt to equity
1.32
Current ratio
7
Quick ratio
6.82
Net debt/EBITDA
-5.94
Margins
EBITDA margin
-14.7%
Gross margin
78.6%
Net margin
-17.2%
Operating margin
-16.6%
Efficiency
Return on assets
-7.9%
Return on equity
-21%
Return on invested capital
-6.5%
Return on capital employed
-8.7%
Return on sales
-16.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVCR stock price

How has the NovoCure stock price performed over time
Intraday
0.62%
1 week
0.18%
1 month
-25.73%
1 year
-30.41%
YTD
-22.06%
QTD
-22.06%

Financial performance

How have NovoCure's revenue and profit performed over time
Revenue
$537.84M
Gross profit
$422.97M
Operating income
-$89.52M
Net income
-$92.53M
Gross margin
78.6%
Net margin
-17.2%
NovoCure's operating income has shrunk by 102% YoY and by 28% QoQ
NovoCure's operating margin has shrunk by 100% YoY and by 29% QoQ
The net income has plunged by 59% YoY and by 13% from the previous quarter
NovoCure's net margin has plunged by 58% YoY and by 14% from the previous quarter

Growth

What is NovoCure's growth rate over time

Valuation

What is NovoCure stock price valuation
P/E
N/A
P/B
13.6
P/S
11.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.08
NVCR's EPS has dropped by 57% year-on-year and by 14% since the previous quarter
The price to book (P/B) is 55% lower than the 5-year quarterly average of 30.1 and 24% lower than the last 4 quarters average of 17.9
The equity has increased by 7% year-on-year
NVCR's price to sales (P/S) is 44% lower than its 5-year quarterly average of 19.7 and 24% lower than its last 4 quarters average of 14.6

Efficiency

How efficient is NovoCure business performance
NVCR's return on sales has dropped by 100% year-on-year and by 29% since the previous quarter
NovoCure's ROIC has plunged by 71% YoY and by 25% from the previous quarter
The company's return on assets fell by 49% YoY and by 11% QoQ
NovoCure's return on equity has decreased by 43% YoY and by 11% QoQ

Dividends

What is NVCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVCR.

Financial health

How did NovoCure financials performed over time
NovoCure's total assets is 59% more than its total liabilities
The company's current ratio fell by 10% QoQ and by 7% YoY
The company's quick ratio fell by 10% QoQ and by 7% YoY
NovoCure's debt is 32% more than its equity
The equity has increased by 7% year-on-year
NVCR's debt to equity is down by 6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.